Theralase Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA88337V1004
CAD
0.15
0.06 (57.92%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Theralase Technologies, Inc. stock-summary
stock-summary
Theralase Technologies, Inc.
Pharmaceuticals & Biotechnology
Theralase Technologies Inc. is a biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (PDCs) to destroy cancer. The Company operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. It is also developing TLC-1000 therapeutic medical laser system. It is developing TLC-3000 medical laser system for the treatment of a range of cancers.
Company Coordinates stock-summary
Company Details
41 Hollinger Rd , EAST YORK ON : M4B 3G4
stock-summary
Tel: 1 416 69952731 416 4478455
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Roger Dumoulin-White
President, Chief Executive Officer, Director
Matthew Perraton
Director
Guy Anderson
Independent Director
Randall Bruder
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 51 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.02

stock-summary
Return on Equity

-335.23%

stock-summary
Price to Book

39.80